Mutations of the BRAF gene in human cancer

@article{Davies2002MutationsOT,
  title={Mutations of the BRAF gene in human cancer},
  author={Helen Davies and G. Bignell and C. Cox and P. Stephens and S. Edkins and S. Clegg and J. Teague and H. Woffendin and M. Garnett and W. Bottomley and Neil M. Davis and E. Dicks and Rebecca Ewing and Yvonne Floyd and Kristian A. Gray and S. Hall and R. Hawes and J. Hughes and V. Kosmidou and Andrew Menzies and Catherine Mould and A. Parker and C. Stevens and S. Watt and S. Hooper and R. Wilson and H. Jayatilake and B. Gusterson and Colin Cooper and J. Shipley and Darren Hargrave and K. Pritchard-Jones and N. Maitland and G. Chenevix-Trench and G. Riggins and D. Bigner and G. Palmieri and A. Cossu and A. Flanagan and Andrew Nicholson and Judy W. C. Ho and S. Y. Leung and S. Yuen and B. Weber and H. Seigler and T. Darrow and H. Paterson and R. Marais and C. Marshall and R. Wooster and M. Stratton and P. A. Futreal},
  journal={Nature},
  year={2002},
  volume={417},
  pages={949-954}
}
  • Helen Davies, G. Bignell, +49 authors P. A. Futreal
  • Published 2002
  • Biology, Medicine
  • Nature
  • Cancers arise owing to the accumulation of mutations in critical genes that alter normal programmes of cell proliferation, differentiation and death. As the first stage of a systematic genome-wide screen for these genes, we have prioritized for analysis signalling pathways in which at least one gene is mutated in human cancer. The RAS–RAF–MEK–ERK–MAP kinase pathway mediates cellular responses to growth signals. RAS is mutated to an oncogenic form in about 15% of human cancer. The three RAF… CONTINUE READING

    Paper Mentions

    INTERVENTIONAL CLINICAL TRIAL
    It is a non-randomized, multicentric, cohort study, combined with a biological sample collection, a clinical data collection and with a genetic and immunologic biomarkers study… Expand
    ConditionsNeoplasms
    InterventionGenetic
    INTERVENTIONAL CLINICAL TRIAL
    The purpose of this study is to evaluate the efficacy and safety of two different schedules of administration of vemurafenib in combination with cobimetinib (continuous and… Expand
    ConditionsMelanoma
    InterventionDrug
    INTERVENTIONAL CLINICAL TRIAL
    MEK162 has shown significant inhibition of tumor growth as a single agent in NSCLC xenograft models in mice and human cancer cells in vitro, which have KRAS and/or other mutations. These… Expand
    ConditionsLungcancer
    InterventionDrug
    BRAF and RAS mutations in human lung cancer and melanoma.
    • 1,005
    • PDF
    BRAF and KRAS mutations in stomach cancer
    • 130
    • Highly Influenced
    • PDF
    BRAF mutations in metastatic melanoma: a possible association with clinical outcome.
    • 217
    • Highly Influenced
    • PDF
    Ras in cancer and developmental diseases.
    • 546
    New insight into BRAF mutations in cancer.
    • 231
    • Highly Influenced
    Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis
    • 270
    • Highly Influenced

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 30 REFERENCES
    Genetic alterations during colorectal-tumor development.
    • 4,710
    • PDF
    Increasing Complexity of the Ras Signaling Pathway*
    • 572
    • PDF
    Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
    • 4,707
    • PDF
    The regulation of normal melanocyte proliferation.
    • 165